TY  - JOUR 
AU  - Molina Guijarro, José Manuel
AU  - Macías, Álvaro
AU  - García Rodríguez, Carolina
AU  - Muñoz Conejero, Eva
AU  - García Fernández, Luis F.
AU  - David, Miren
AU  - Núñez Llorente, Lucía
AU  - Martínez Leal, Juan Fernando
AU  - Moneo, Victoria
AU  - Cuevas, Carmen
AU  - Lillo, María Pilar
AU  - Villalobos Jorge, Carlos
AU  - Valenzuela, Carmen
AU  - Galmarini, Carlos María
PY  - 2011
SN  - 1932-6203
UR  - http://uvadoc.uva.es/handle/10324/45067
AB  - Irvalec is a marine-derived antitumor agent currently undergoing phase II clinical trials. In vitro, Irvalec induces a rapid loss of membrane integrity in tumor cells, accompanied of a significant Ca2+ influx, perturbations of membrane conductivity,...
LA  - eng
PB  - Public Library of Science
KW  - Antitumor drugs
KW  - Fármacos antitumorales
KW  - Plasma membrane
KW  - Membrana plasmática
TI  - Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells
DO  - 10.1371/journal.pone.0019042
ER  -